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Proteoglycans and glycosaminoglycans have the com­
mon structural characteristics of linear polysaccharide 
chains consisting of a hexosamine alternating with an­
other sugar. They play an important role in skin as part 
of the support matrix of connective tissue, and may be 
related to cell-cell, and cell-matrix interactions. In gen­
eral the polysaccharide chains are covalently linked to 
protein and may contain varying amounts of sulfate 
resulting in a strong negative charge. Biosynthesis con­
sists of the formation of the protein core followed by the 
sequential addition of sugars and sulfate to the non­
reducing ends of growing chains. The synthetic process 
is highly organized with the final polysaccharide po­
lymerization and sulfation taking place in the Golgi. 
Degradation of the proteoglycans is less well understood 
but probably involves endoglycosidases, exoglycosi­
dases, and proteases which work in concert to degrade 
these substances. 
The proteoglycans and glycosaminoglycans of skin represent 
a group of compounds that are related to one another by 
common structural characteristics. Their trival names are: 
Hyaluronic acid 
Chondroitin 
Chondroitin 4-sulfate (formerly called chondroitin sulfate A) 
Chondroitin 6-sulfate (formerly called chondroitin sulfate C) 
Dermatan sulfate (formerly called chondroitin sulfate B) 
Heparin 
Heparan sulfate (or heparitin sulfate) 
These substances play an important role as part of the 
supporting matrix of connective tissue. They function in main­
taining salt and water distribution and control a "domain," so 
that a volume of water as much as 1,000 times the volume of 
the proteoglycan can be contained within the molecule. In 
addition, it would appear that these molecules may be directly 
involved in cell-cell and cell-matrix interactions, and may be of 
importance in directing cell behavior. 
TERMINOLOGY 
Historically, the term "mucopolysaccharide" has been ap­
plied to these substances in order to describe a polysaccharide 
material that was viscous or mucinous (from the Latin, slimy). 
Initially, only the structure of the polysaccharide (glycosami­
noglycan) portions of these molecules was recognized, but sub­
sequently, it has become clear that the polysaccharides are 
usually linked covalently to protein. This complication in struc­
ture has led to further difficulties in nomenclature. Because of 
historic and widespread use, the term mucopolysaccharide con­
tinues to be used as an all inclusive name. Thus, mucopolysac­
charide is sometimes used when one is referring to the polysac­
charide portion alone, or when one is referring to the entire 
polysaccharide-protein (proteoglycan) combination. The term 
is not rigorously defined. 
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Skin", edited by L. Goldsmith, Oxford University Press. It is published 
with the permission of Oxford University Press. 
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The term "glycosaminoglycan" was introduced in order to 
clarify some of the confusion over the use of "muco­
polysaccharide." This term is descriptive of the polysaccharide 
(glycan) structure containing hexosamines (glycosamino), and 
does not include the protein moiety. The compounds listed 
above by trivial name plus keratan sulfate (not found in skin), 
are the only substances in vertebrates that satisfy these struc­
tural criteria. However, some substances in lower animals and 
bacteria fulfill the requirements of being a glycosaminoglycan. 
These compounds are clearly separate from the vertebrate 
compounds by virtue of totally different function, location, etc. 
Since hyaluronic acid has not been conclusively shown to be 
linked covalently to protein, the term proteoglycan cannot be 
correctly applied. 
STRUCTURE 
Glycosaminoglycan 
The structural characteristics of the skin glycosaminoglycans 
are similar to glycosaminoglycans from other tissues. The 
chains consist of hexosamine (either glucosamine or galactosa­
mine), alternating with another sugar (glucuronic acid or idu­
ronic acid). Although an individual chain may have a mixture 
of uronic acids (i.e., some glucuronic acid and some iduronic 
acid) the hexosamine will always be all glucosamine or all 
galactosamine. Because the hexosamine occurs as every other 
sugar, it is most convenient to think of the glycosaminoglycans 
as compounds consisting of multiple disaccharide repeating 
units as shown in Fig 1. In most cases, these repeating disac­
charide units are similar within a single chain, but heparin and 
heparan sulfate have a more complicated structure and cannot 
be adequately represented in this fashion. A representative 
section of these compounds is shown in Fig 2. Variation in 
sulfate content and the uronic acid occur throughout the chain. 
In addition, heparan sulfate has variations in the amount of N­
sulfate and N -acetyl. 
The glycosaminoglycan chains of the various compounds 
range in size from approximately 15 disaccharide units (several 
thousand Daltons) to 5,000 disaccharide units (several million 
Daltons) and are linear (unbranched). All hexosamines are 
substituted on the amino group with either acetyl or sulfate. In 
addition, most glycosaminoglycans have ester O-sulfate on one 
or both sugars of a repeating unit. All the glycosaminoglycans 
are highly anionic by virtue of their sulfate groups (as many as 
three per disaccharide unit) and/or their uronic acids. The 
sugars are linked by ex or fJ glycosidic bonds and are 1,3 or 1,4 
as detailed in the Table. 
Oligosaccharide Linkage 
The glycosaminoglycan portions of chondroitin 4-sulfate and 
6-sulfate, dermatan sulfate, heparin, and heparan sulfate are 
each linked at their reducing end to a trisaccharide consisting 
of galactosyl-galactosyl-xylose (Fig 3) [1]. Xylose is glycosidi­
cally linked to the hydroxyl of serine in the protein chain; the 
first sugar of the glycosaminoglycan chain (linked to the galac­
tose) is always a glucuronic acid. This first glucuronic acid 
could be considered to be a part of the linkage oligosaccharide 
since biosynthetically, it is added by a specific enzyme different 
from the enzyme that is involved in the incorporation of glu­
curonic acid into the polysaccharide chain. 
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FIG. 1. Disaccharide repeating units of glycosaminoglycans. 
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FIG. 2. Typical oligosaccharide structures of heparin and heparan 
sulfate. 
Proteoglycan 
The proteoglycan structure has only been described in detail 
for cartilage [2]; however, skin proteoglycan is probably similar. 
In cartilage the glycosaminoglycan chains (1-5 x 104 MW) are 
connected through the above described oligosaccharide linkage 
to a protein core molecule (1-2 X 105 MW), forming a proteo­
glycan unit, or monomer. Each proteoglycan may have 50 or 
more similar glycosaminoglycan chains attached to this core in 
a "bottle brush" configuration (Fig 4) so that the total MW 
may be more than 106• The chains may vary in size and sulfate 
content within a single proteoglycan unit, resulting in a high 
degree of heterogeneity. The structures of the various core 
proteins have not been defined, even to the extent of whether 
or not there are repeating sequences. 
As many as 100 individual proteoglycan monomers in turn 
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can be attached non-covalently around a core of hyaluronic 
acid to form aggregates of 100-150 X 106 MW (Fig 4) [2,3]. The 
proteoglycans are spaced along the chain at intervals of 10 
disaccharide units, and a separate protein has been shown to 
be involved in the non-covalent link. The aggregate can be 
associated to proteoglycan monomer by high salt concentration, 
and at least part can be re-aggregated by lowering the salt 
concentration. 
BIOSYNTHESIS 
Much of the early work on biosynthesis of glycosaminogly­
cans or proteoglycans used skin as a source of proteoglycan­
synthesizing tissue. Although subsequent work has mainly been 
with cartilage or mast cell tumors, the pathways of synthesis 
should be the same for skin. 
Precursor activation 
The synthesis of the glycosaminoglycan portion of proteogly­
cans proceeds through uridine sugar nucleotide precursors. (A 
representative structure is shown in Fig 5). Sugar nucleotides 
are formed by a pyrophosphorylase type of reaction, such as: 
Uridine-P-P-P + N-Acetylglucosamine-I-P 
(UTP) 
Uridine-P-P-N-acetylglucosamine + pop 
(UDP -N -acetylglucosamine) 
Components of the glycosaminoglycan portion of proteoglycans 
Approximate 
MWofgly- Major component Location Linkage cosaminogly- sugars of sulfate 
can chains 
Hyaluronic acid 5-50 X 10' N -Acetylglucosa- {3-1,4 
mme 
Glucuronic acid {3-1,3 
Chondroitin 4- 2-5 X 104 N -Acetylgalacto- 4 {3-I,4 
sulfate (chon- samme 
droitin sulfate Glucuronic acid {3-I, 3 
A) 
Chondroitin 6- 2-5 X 104 N -Acetylgalacto- 6 {3-1, 4 
sulfate (chon- samme 
droitin sulfate Glucuronic acid {3-1, 3 
C) 
Dermatan sul- 2-5 X 104 N -Acetylgalacto- 4 {3-1, 4 
fate (chondro- samme 
itin sulfate B) Iduronic acid 2 a-l, 3(l 
Glucuronic acid {3-I, 3 
(trace) 
Heparin 0.5-4 X 104 Glucosamine 6, N a-I, 4 
Glucuronic acid {3-1, 4 
Iduronic acid 2 a-I, 4" 
Heparan sulfate 1-5 X 104 Glucosamine 6, N a-I, 4 
N-Acetylglucosa- a-I, 4 
mine 
Glucuronic acid {3-I,4 
Iduronic acid 2 0'-1,4([ 
" These linkages are identical to the {3 1-3 or {3 1-4 linkages found in 
hyaluronic acid and chondroitin sulfates or heparin. However, iduronic 
acid has an L rather than a D configuration, which results in these 
bonds being designated as a rather than {3. 
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FIG. 3. Oligosaccharide linkage between glycosaminoglycans and 
protein core. 
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FIG. 4. Proteoglycan monomer and aggregate. 
URIDINE DIPHOSPHATE GLUCURONIC ACID (UDPGlcUA) 
COOH 
0- 0 0 II II OH O-P-O-P-O HO I I '-....CH2 
OH OH OH 
3' PHOSPHOADENOSINE 5'-PHOSPHOSULFATE (PAPS) 
o 0 
II II 
:)cN H2 
N N� '\ l.
N I .> 
HO-S-O-P-� 
g 6H CH2 
OH 
I 
HO-P- -OH 
II 
o 
FIG. 5. Structure of uridine diphosphate glucuronic acid and 3'­
phosphoadenosine 5' -phosphosulfate. 
and can be modified to form a different sugar nucleotide such 
as: 
UDP-N-acetylglucosamine UDP-N -acetylgalaetosamine. 
These types of reactions have been demonstrated in prepara­
tions from several tissues that synthesize proteoglycans, includ-
ing skin and cartilage. Thus, as shown in Fig 6, the key inter­
mediate compounds related to glycosaminoglycans are UDP­
glucose and UDP-N-acetylglucosamine. Both of these can be 
formed by reaction of UTP with a sugar-l-P(either glucose-l-P 
or N-acetylglucosamine-l-P) in the presence of homogenates 
from proteoglycan-producing tissues. UDP-Glucose can be ox­
idized to form UDP-glucuronic acid [4] which can in turn be 
de carboxylated to form UDP-xylose [5]. This latter reaction 
has not been shown with enzymes from skin, but undoubtedly 
takes place. Although UDP-iduronic acid has been shown to be 
formed from UDP-glucuronic acid with skin preparations [6], 
this is not the pathway for iduronic acid formation in glycos­
aminoglycans [7]. Both UDP-glucose and UDP-N-acetylglu­
cosamine can undergo epimerization at the C-4 position to form 
UDP-galactose and UDP-N-acetylgalactosamine [8] respec­
tively. Thus, the synthetic steps in the formation of all the 
sugar nucleotides necessary for synthesis are known to occur in 
proteoglycan-producing tissues. It is possible that sugar nucleo­
tides with bases other than uridine might be involved in pro­
teoglycan synthesis, but there is no evidence for this at present. 
The sugar moieties of the glycosaminoglycans of skin have 
been shown by use of labeled sugars to arise from glucose 
without any rearrangement of the label [9]. The pathways are 
shown in Fig 6. In addition, alternate pathways have been found 
in liver involving the direct phosphorylation of galactose and 
phosphorylation and acetylation of glucosamine with subse­
quent conversion to the appropriate sugar nucleotides [10,11]. 
These pathways might also be involved in other tissues but 
have not as yet been demonstrated. Other pyrophosphorylase 
reactions (such as UTP with glucuronic acid-I-P and xylose-l­
P) have not been observed in mammalian systems, although 
some of these reactions occur in plants. 
The intermediate for sulfation of glycosaminoglycans is 3'­
phospho adenosine 5'-phosphosulfate or PAPS [12] (Fig 5) . The 
reactions involved in synthesis of this compound are shown in 
Fig. 6, and have been described in many tissues, including skin 
[13]. 
Two of the sugar nucleotides have been shown to act as 
feedback inhibitors of key enzymes in the pathway of sugar 
nucleotide formation in liver. It is likely that they function 
similarly in glycosaminoglycan-producing tissues. UDP-N-Ace­
tylglucosamine has been shown to inhibit the formation of 
glucosamine (L-glutamine-D-fructose-6-phosphate aminotrans-
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FIG. 6. Biosynthesis of the carbohydrate portion of proteoglycan. 
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ferase) [14]. Thus an excess of UDP-N-acetylglucosamine 
would turn off its own synthesis, and control the amount of 
hexosamine available for glycosaminoglycan formation. UDP­
Xylose has been shown to inhibit the oxidation of UDP-glucose 
to UDP-glucuronic acid (UDP-glucose dehydrogenase) [15]. 
This turns off the synthesis of the uronic acid nucleotides, thus 
affecting the availability of uronic acid for synthesis of glycos­
aminoglycans. In addition, the formation of UDP-xylose would 
be limited by the supply of its precursor, UDP-glucuronic acid. 
Therefore, the formation of the oligosaccharide that links pro­
tein to glycosaminoglycan would be controlled. 
It is assumed that all cells capable of synthesizing proteogly­
cans contain the machinery for synthesizing all the necessary 
precursors, since phosphorylated sugars and sugar nucleotides 
do not readily enter the cell. Although the presence of all the 
necessary enzymes has been documented in one or another of 
the proteoglycan-synthesizing tissues, it has not been investi­
gated thoroughly in skin because of the assumption that the 
enzymes would be present. 
Protein core 
It has been established that synthesis of proteins is necessary 
before formation of the glycosaminoglycan can take place. This 
has been demonstrated by pulse-chase experiments [16] and by 
experiments showing that puromycin inhibited synthesis of 
proteoglycans, but did not inhibit the transfer of sugars to an 
endogenous proteoglycan acceptor [17]. 
Oligosaccharide linkage 
Biosynthesis of the galactosyl-galactosyl-xylosyl oligosaccha­
ride that links protein to the polysaccharide portions of the 
proteoglycan appears to take place by sequential addition of 
sugars to a protein acceptor. The oligosaccharide appears to be 
identical for most of the proteoglycans, so that synthesis is 
probably similar in each case. 
Transfer of [14C]xylose from UDP-C4C]xylose to the hydroxyl 
of a serine on endogenous protein acceptors has been demon­
strated with enzyme from cartilage and mast cell tumors 
[18,19]. The specificity of this reaction is not clear, but it is 
likely that the activity is related to the synthesis of chondroitin 
sulfate and heparin. 
The incorporation ofC'C]galactose from UDP-[14C]galactose 
onto an endogenous protein acceptor has been demonstrated 
with preparations from cartilage (20). Treatment of the product 
with alkaline borohydride resulted in [14C]galactosyl-xylitol, 
thus demonstrating that the galactose was transferred to a 
xylose attached to a protein. However, no stimulation of galac­
tose incorporation was achieved when UDP-xylose was present. 
Thus, the sequential addition could not be demonstrated di­
rectly but remained only presumptive. 
The amounts of incorporation into endogenous acceptors 
have been relatively low. Furthermore, it is difficult to distin­
guish between the amount of enzymatic activity and the amount 
of acceptor as the limiting factors in the activities of these 
preparations. For these reasons, synthetic exogenous acceptors 
have been utilized to test the relative activities of the enzymes 
and to help in characterization of these enzymes. Various com­
pounds such as xylose, xylosyl-serine, galactosyl-xylose, and 
galactosyl-xylosyl-serine have been utilized with UDP-C4C]ga­
lactose and particulate preparations from chick cartilage. By 
use of experiments with mixed substrates, it has been demon­
strated that there are 2 separate galactosyl transferases [20]. 
The same particulate preparation described above was shown 
to catalyze the addition of glucuronic acid into galactosyl-galac­
tosyl-xylose when this trisaccharide was added to the incuba­
tion mixture [21]. Galactosyl-galactose and galactosyl-galacto­
syl-xylosyl-serine also acted as acceptors. By use of mixed 
substrate experiments (galactosyl-galactose and oligosaccha­
rides obtained after degradation of chondroitin-6-sulfate) it was 
shown that this enzyme was not the same as the one involved 
in addition of glucuronic acid for polymerization. Similar ex-
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periments with similar conclusions have been performed with 
enzyme preparations from chick brain [22]. 
Glycosaminoglycan polymerization 
As with the formation of the oligosaccharide link, the glycos­
aminoglycan chains are synthesized from sugar nucleotide pre­
cursors. Thus, UDP-glucuronic acid and UDP-N-acetylglucos­
amine are presursors for hyaluronic acid [23], heparin [24] and 
presumably, heparan sulfate; and UDP-glucuronic acid and 
UDP-N -acetylgalactosamine are precursors for chondroitin sul­
fate [25,26]. 
In chondroitin synthesis, the sugars are added alternately, 
one at a time [27,28] and some glycosaminoglycan chains ter­
minate in hexosamine, while others terminate in uronic acid 
[29]. It is likely that other glycosaminoglycans are formed 
similarly, although this has not been demonstrated directly. 
The nature of the endogenous primers for these polymeriza­
tions have not been completely defined, although the reactions, 
in part, represent elongation of glycosaminoglycan chains that 
are already of considerable size. The primer is bound to protein 
which may be larger than the final protein of the proteoglycan 
[30], suggesting some postsynthetic modification. The whole 
complex is part of a particulate fraction of cells and may be 
attached in turn to the active enzyme. When oligosaccharide 
primers are utilized instead of the endogenous primers, the 
polymerization only proceeds to the addition of a few sugars, 
rather than the polymerization of a long chain [28]. This would 
suggest that the natural primer and enzyme may be in juxta­
position in order to facilitate optimal biosynthesis. 
Sulfation apparently occurs by the direct transfer of a sulfate 
group from PAPS to the appropriate sites of the glycosamino­
glycan. Even though a sulfated sugar nucleotide (UDP-N-ace­
tylgalactosamine-4-S) has been described, it does not appear to 
be an intermediate [31]. The possibility of other intermediates 
does exist, however, since the enzymes accomplishing sulfation 
have not been purified and various cofactors might be present 
in the crude preparations utilized in most experiments. 
Incorporation of sulfate into proteoglycans has been demon­
strated most extensively with preparations from cartilage [32], 
and mast cell tumors [33], although other tissues, including 
skin, have been used as sources for the enzymatic activity 
[13]. There appears to be a wide range of glycosaminoglycans 
that will accept sulfate with enzymes from a single source, so it 
has not been clear how specific the sulfotransferases are. The 
synthesis of highly sulfated chondroitin sulfate and heparin 
glycosaminoglycan was accomplished with cell-free systems. In 
both of these cases, the particulate enzyme preparations that 
catalyzed glycosaminoglycan polymerization also catalyzed the 
incorporation of sulfate onto the newly formed glycosaminogly­
can. In this instance, as in the case of polymerization itself, it 
would appear that the optimal transfer of sulfate is dependent 
upon a degree of organization of the glycosaminoglycan accep­
tor with protein and perhaps with the enzyme. 
Sulfation can be completed on an already completely pre­
formed glycosaminoglycan or may take place at the same time 
as polymerization. It occurs as an "all or nothing" phenomenon 
[32], with some molecules being essentially completely sulfated 
and others not sulfated at all; no significant amount of partly 
sulfated chains are found. 
An unusual sulfation reaction has been found to take place in 
the course of heparin synthesis, and probably applies to heparan 
sulfate. Heparin contains N-sulfate in contrast to the N-acety­
lation found in other glycosaminoglycans. However, the synthe­
sis proceeds through the formation of a glycosaminoglycan 
containing N-acetylglucosamine [24] which is then de-acety­
lated with replacement of the acetyl by sulfate [34,35]. The 
formation of the O-sulfate on the heparin appears to be similar 
to that of chondroitin sulfate. 
The formation of the iduronic acid moiety of heparin and 
dertnatan takes place by epimerization of glucuronic acid to 
iduronic acid after polymerization is complete [7,36]. In the 
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case of heparin this epimerization may be linked to sulfation of 
the iduronic acid. 
There is a distinct separation between the enzymes of pre­
cursor activation and those of macromolecular assembly. Most 
of the enzymes involving formation of sugar nucleotides and 
PAPS are found in a high speed supernatant fraction from 
tissue homogenates, implying that they are cytoplasmic in 
origin. The activities involved in glycosaminoglycan assembly 
on the other hand, are particulate, being found in a crude 
"microsomal" fraction. This would imply that these enzymes 
are either attached to, or part of membranous structures in the 
cell. The enzymes involved in sulfate transfer from PAPS are 
readily found in the supernatant fraction, but the activity there 
appears to be relatively low. The maximal transfer of sulfate is 
found with the same microsomal fractions that promote poly­
saccharide polymerization [32,33]. It seems reasonable to sup­
pose that the state of the membrane-bound proteoglycan sub­
strate contributes greatly to the overall efficiency of sulfation. 
Radioautographic studies to locate the sites of proteoglycan 
biosynthesis have indicated that sulfation and probably glycos­
amino glycan polymerization take place in the Golgi apparatus 
[37,38], while the synthesis of protein occurs on the rough 
endoplasmic reticulum. This is in agreement with work on 
glycoprotein biosynthesis with isolated Golgi preparations 
[39]. Recently, isolated Golgi preparations from mast cells have 
been shown to contain essentially all of the glycosaminoglycan­
synthesizing activity [40]. 
Certain aspects of biosynthesis, such as the formation of the 
protein portion, the organization of the synthesis within the 
cell, and the control of the synthetic processes, are largely 
unsolved. These may prove to be of great importance, since it 
has become increasingly apparant that pathological processes 
are generally related to alterations of aspects of control and 
metabolic organization rather than simple direct effects on 
individual steps in the metabolic pathways. This would be 
expressed on a cellular basis resulting in multiple changes, 
rather than as a single, easily described enzyme effect. It is 
probable that most effects on proteoglycan or glycosaminogly­
can formation are secondary to more widespread changes in the 
cell. Changes in glycosaminoglycan production have been de­
scribed in cultures of skin fibroblasts from patients with Mar­
fan's syndrome [41] and diabetes [42]. In each of these cases, 
there were changes in the amount of one or another of the 
glycosaminoglycans. 
DEGRADATION 
Turnover 
The half-life of skin hyaluronic acid in vivo (young rabbit 
and rat) has been shown to be 2 to 5 days; skin chondroitin 
sulfate has been shown to have a half-life of 7 to 14 days, while 
dermatan sulfate in skin of young animals was reported to have 
a half-life of 7 to 10 days [43,44]. Dermatan sulfate half-life in 
older animals was somewhat longer [45]. Chondroitin sulfate in 
costal cartilage of rats was found to have a half-life of 17 days 
[46]. 
Incorporation of radioactively-labeled precursors and turn­
over of these precursors has also been studied in synovial cells 
(47) and in cartilage. Simultaneous incorporation of CGS]sulfate, 
[14C]proline and [,4C]phenylalanine into chondrocytes has been 
shown (48) with both the 14C-labeled and :lr'S-labeled material 
being turned over at the same rate. This has also been found 
with [14C]lysine and C5S]sulfate (49) indicating a concomitant 
turnover of both the protein and the glycosaminoglycan moie­
ties of the proteoglycan. 
Radioautography of rat mast cells has been utilized to show 
that sulfate is incorporated into heparin and then slowly lost. 
Approximately 75% of the heparin was found to be present after 
18 days [50]. When ['4C]hyaluronic acid was injected into 
guinea pigs [51], most of the label was found to be excreted as 
hyaluronic acid with less being metabolized. Rats injected with 
chondroitin ['l"S]sulfate were found to excrete free [,lGS]sulfate 
in the urine [52], indicating that a sulfatase was present in 
tissues of the rats. When chondroitin 4-sulfate, chondroitin 6-
sulfate, dermatan sulfate, and heparan sulfate were injected 
into dogs, as much as 60% of the injected glycosaminoglycan 
could not be accounted for [5a]. It was suggested that this 
material might have been degraded by the tissues. When small 
amounts of CGS]heparin were injected into dogs, radioactivity 
was obtained quantitatively in the urine (54) as inorganic 
C5S]sulfate. When larger doses of C"S]heparin were utilized, 
there was some C5S]heparin as well as C"S]sulfate found in the 
unne. 
It can readily be seen by the above studies that the mecha­
nism of the proteoglycan turnover is not clear. It would appear 
that there is probable degradation of the glycosaminoglycan 
moiety, but the degree to which this takes place is not known. 
The studies indicate that at least some of the glycosaminogly­
cans can be excreted intact in the urine. Therefore, it is possible 
that both mechanisms for turnover exist concomitantly. 
Endoglycosidases 
Enzymatic degradation of glycosaminoglycans or proteogly­
cans was first noted as "spreading factor" [55]. When India ink 
or similar material was injected subcutaneously, an increased 
diffusability of the dye was noted if a "spreading factor" was 
injected at the same time. Identification of these factors as 
glycosaminoglycan-degrading enzymes helped to stimulate in­
terest in, and led to studies defining the structures of the 
glycosaminoglycans (mainly in the laboratory of Karl Meyer). 
It was assumed that enzymes similar to the "spreading factors" 
were probably involved in glycosaminoglycan breakdown and 
tunrover in vivo. 
The best-defined glycosaminoglycan lyase is the hyaluroni­
dase that is found in testicular tissue. This enzyme degrades 
hyaluronic acid to a family of oligosaccharides ranging in size 
from tetrasaccharide to larger even-numbered oligosaccharides 
[56]. When hyaluronic acid is incubated with the enzyme, the 
primary product is the tetrasaccharide with a small amount of 
larger oligosaccharides and a small amount of disaccharide. The 
disaccharide has been identified as N-acetylhyalobiuronic acid, 
and the tetrasaccharide consists of 2 N -acetylhyalobiuronic acid 
units linked in the same fashion as they are linked in the intact 
hyaluronic acid molecule. The larger oligo saccharides are mul­
tiples of this. 
The enzyme has been found to be an endo-,B-N-acetylhexo­
saminidase, attacking ,B-linked N -acetylglucosaminyl groups at 
random within the chain, with a preferential reaction on the 
larger molecules rather than on smaller oligo saccharides [57]. 
Thus, the hyaluronic acid molecule initially can be depolymer­
ized rapidly, with consequent loss of viscosity. Further degra­
dation results in release of measurable amounts of reducing 
sugars, but completion of degradation requires a longer time. 
The enzyme has been shown to be a transglycosylase, capable 
of transferring disaccharide units from one molecule to another 
[57,58]. Thus, when hexasaccharide is incubated with testicular 
hyaluronidase, some octasaccharide can be found as well as 
tetrasaccharide. 
Desulfated chondroitin, chondroitin 4-sulfate, and chondro­
itin 6-sulfate have also been shown to be degraded by the 
testicular enzyme, resulting in oligosaccharide products similar 
in size to those from hyaluronic acid [58,59]. Sulfate groups are 
not removed during this reaction. Degradation of chondroitin 
sulfate is not so rapid as degradation of hyaluronic acid [59], 
while nonsulfated chondroitin reacts similarly to hyaluronic 
acid in rapidity of degradation. 
A hyaluronidase from rat skin has also been described [60]. 
This enzyme acts in a fashion similar to that of testicular 
hyaluronidase as a ,B-N-acetylhexosaminidase with activity as 
a transglycosylase. However, it differs somewhat from testicular 
hyaluronidase, yielding mainly hexasaccharide and larger prod­
ucts with no disaceharide and only a small amount of tetrasae­
charide. It has been conduded that the amount of hyaluroni­
dase obtained in fractions from skin is sufficient to account for 
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all the necessary degradation of hyaluronic acid in the known 
turnover of hvaluronic acid in skin tissue. The enzyme has been 
noted to hav� activity in degrading chondroitin 4-sulfate and 
chondroitin 6-sulfate. Hyaluronidase has also been found in 
embryonic chick skin and in chick cell cultures, but not in 
human skin fibroblast cultures [61]. 
Another source of skin hyaluronidase has been found in the 
back skin of tadpoles [62]. It has been shown to be active 
throughout all of the stages of tadpole metamorphosis, but not 
to be present in the adult bullfrog [63], suggesting that glycos­
amino glycan-degrading enzymes might have an active part in 
tissue remodeling and growth. The pH optimum of this hyal­
uronidase is somewhat higher that that of skin hyaluronidase 
of mammalian tissues. 
It should be noted that no skin endoenzymes have been 
demonstrated that are capable of significantly degrading der­
matan sulfate or heparan sulfate, both prime components of the 
proteoglycans of skin. 
Since dermatan sulfate contains a small amount of glucuronic 
acid in addition to iduronic acid [64], it has been suggested that 
hyaluronidase can cause some depolymerization by acting at 
these points. Enzymes from spleen [65], liver [66] and platelets 
[67], have been reported to be capable of degrading heparin or 
heparan sulfate to small oligosaccharides. There have also been 
other reports of endoenzyrnes that act on heparin or heparan 
sulfate in a more limited fashion [68-70]. Some of these enzymes 
may be involved in processing proteoglycans during synthesis 
rather than in true degradation. With these exceptions and a 
few isolated suggestions that derma tan sulfate might be de­
graded by mammalian tissues, there have been no other descrip­
tions of mammalian enzymes capable of degrading these com­
pounds. Thus, the nature of the degradation in vivo remains 
unknown. 
Exoglycosidases and sulfatases 
The products of degradation of glycosaminoglycans by most 
glycosaminoglycan lyases are oligosaccharides containing a glu­
curonic acid moiety at their nonreducing ends [71]. ,B-Glucuron­
idase will attack these ends, yielding free glucuronic acid and a 
terminal N -acetyl hexosamine on the remaining oligosaccharide 
[72]. This moiety can in turn be attached by N-acetylhexosa­
minidases [71,72]. Xylosidases [73] and galactosidases [74] have 
also been found in mammalian tissue, suggesting that they 
might be involved in degradation of the oligosaccharide linkage 
between protein and glycosaminoglycan. 
To date, the glycosidases described above have been found 
to act only as exoglycosidases; that is, they attack only a 
terminal non-reducing sugar and are not capable of cleaving 
within an intact glycosaminoglycan or oligosaccharide. The 
sulfatases also have no action on the intact glycosaminoglycan, 
only cleaving sulfate from the nonreducing terminal end of 
oligosaccharides. Therefore, these enzymes would have to act 
sequentially from the nonreducing end of the glycosaminogly­
can. 
During the last few years, a series of degradative enzymes 
have been examined in cultures of skin fibroblasts. An extensive 
literature exists concerning the presence or absence of these 
various enzymes and their relationships to the genetic muco­
polysaccharidoses [75]. It has been shown that intracellular 
oligosaccharides or small glycosaminoglycans can be degraded 
from their nonreducing ends by removal of terminal glycosyl 
groups and/or sulfate. Absence of one or more of the degrada­
tive enzymes will result in a glycosaminoglycan storage disease 
due to inability to degrade the remainder of the molecule. Many 
of these diseases have been described, with a single missing 
degradative enzyme for each. Information has been obtained 
regarding these missing enzymes and the manner in which cells 
can incorporate these enzymes [76]. Further description is 
beyond the scope of this review. 
There have been other suggestions regarding the role that 
degradation of proteoglycans might play in pathological condi-
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tions, but only in the case of the genetic mucopolysaccharidoses 
is there a good indication that a relationship exists. 
Protease 
One possible method of turning over proteoglycans in tissues 
is by degradation of the protein moiety. This has been most 
graphically demonstrated by experiments involving the injec­
tion of the proteolytic enzyme, papain, into rabbit ears [77]. 
This procedure resulted in a rapid loss of cartilage rigidity 
accompanied by mobilization and excretion of glycosaminogly­
cans in the urine. Thus, it has been conclusively demonstrated 
that proteolytic enzymes can mobilize large amounts of glycos­
aminoglycans from connective tissue in vivo. 
Acid proteases (cathepsins) of bone and cartilage have been 
shown to be capable of degrading the protein portion of proteo­
glycans [78], followed by solubilization of the glycosaminogly­
cans. 
Factors Affecting Metabolism 
There have been many studies concerning the relative 
amounts of glycosaminoglycans found in skin from individuals 
with a variety of conditions, or effects of a variety of agents 
such as steroids, aspirin, etc. [79 ,80]. There is no good evidence 
that these changes in glycosaminoglycan production or degra­
dation are primary rather than secondary to other more fun­
damental effects on cells. There have been notable differences 
found regarding the amount and type of glycosaminoglycans in 
skin from different aged individuals. Here again, there is no 
good evidence that these changes in glycosaminoglycans are 
primary to changes in aging rather than reflecting other fun­
damental changes in cell metabolism. 
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